Nicotinamide Cuts Rate of Nonmelanoma Skin Cancer in Those at High Risk
May 14, 2015 | Clinician Reviews
Author and Disclosure Information
Key clinical point: Nicotinamide, an inexpensive oral vitamin, protects against nonmelanoma skin cancer in patients at high risk.
Major finding: Patients taking nicotinamide had a 23% lower rate of new basal cell and squamous cell carcinomas.
Data source: A randomized, placebo-controlled phase III trial among 386 patients with past nonmelanoma skin cancers.
Disclosures: Dr. Damian disclosed no relevant conflicts of interest. The study was funded by the National Health & Medical Research Council.
FROM THE ASCO 2015 PRESSCAST
Dr. Damian disclosed no relevant conflicts of interest. The study was funded by the National Health & Medical Research Council.
